Prognostic evaluation was performed in 198 patients with chronic systolic HF: 99 patients who died from cardiovascular cause within 3 years were individually matched for age, sex, and HF etiology (ischemic vs. not) with 99 patients who were alive after 3 years of HF evaluation. We performed a proteomic profiling of 15 apolipoproteins: Apo-A1, -A2, -A4, -B100, -C1, -C2, -C3, -C4, -D, -E, -F, -H, -J, -L1 and -M using LC-MRM-MS.
In univariate analysis, the levels of Apo-B100 and -L1 were significantly lower and the levels of Apo-C1, -J and -M were significantly higher in patients who died from cardiovascular cause as compared with patients alive. In the final statistical model, Apo-C1, Apo-J and Apo-M improved individually the prediction of cardiovascular death. Ingenuity pathway analysis indicated these 3 Apo in a network associated with lipid metabolism, atherosclerosis signaling and RXR activation.
Proteomic profiling of apolipoproteins using LC-MRM-MS might be useful in clinical practice for risk stratification of HF patients. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.